LFCR
Lifecore Biomedical, Inc.7.71
-0.17-2.16%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
288.87MP/E (TTM)
-Basic EPS (TTM)
-1.27Dividend Yield
0%Recent Filings
8-K
8-K
8-K
Lifecore approves transition bonus plan
Lifecore Biomedical approved a CY 2025 Transition Period Bonus Plan on September 22, 2025, covering May 26 to December 31, to align with its shift to a calendar-year fiscal structure. The plan ties executive bonuses—100% of base for CEO Paul Josephs, 60% for CFO Ryan Lake, and 50% for Chief Legal Officer Thomas Salus—to 80% financial goals like Adjusted EBITDA and revenue, with no payouts unless minimum EBITDA hits. Yet executives must stay employed through year-end to collect. This setup incentivizes performance amid the fiscal tweak, but clawback policies loom.
8-K
Auditor switch amid control weaknesses
Lifecore Biomedical dismissed BDO as its auditor and appointed KPMG on August 12, 2025, for the transition period ending December 31, 2025. BDO's reports flagged ongoing material weaknesses in internal controls over financial reporting, tied to COSO components like risk assessment and monitoring, stemming from non-standard transactions and business changes. The switch aims to address these issues. Weaknesses persist.
8-K
Lifecore's growth strategy unveiled
Lifecore Biomedical unveiled an investor presentation on August 12, 2025, outlining its aggressive growth strategy as a CDMO leader in injectables, targeting 12%+ revenue CAGR and 25%+ Adjusted EBITDA margins mid-term amid a market doubling by 2030. Fiscal 2025 delivered $128.9M revenues and $19.5M Adjusted EBITDA, with seven-month transition guidance of $74M-$76M revenues and $12M-$14M Adjusted EBITDA, fueled by pipeline commercialization and new business. Capacity now supports ~$300M annual revenue potential. Yet risks like regulatory hurdles loom large.
IPO
Website
Employees
Sector
Industry
BHC
Bausch Health Companies Inc.
6.93+0.02
BIOE
Bio Essence Corp.
0.05+0.00
CRLBF
Cresco Labs Inc.
1.75+0.45
FLGC
Flora Growth Corp.
8.84+0.39
HYEX
HEALTHY EXTRACTS INC.
1.99-0.22
INCR
Intercure Ltd.
1.45+0.05
LEEEF
LEEF BRANDS INC
0.22+0.02
LIFD
LFTD Partners Inc.
0.28+0.00
LVRLF
CordovaCann Corp.
0.03+0.00
RGC
Regencell Bioscience Holdings L
16.70-0.56